Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hirsutism | 4 | 2018 | 69 | 1.120 |
Why?
|
| Gonadotropin-Releasing Hormone | 20 | 2021 | 1185 | 1.010 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2010 | 1202 | 0.690 |
Why?
|
| Amenorrhea | 8 | 2021 | 485 | 0.650 |
Why?
|
| Hair Removal | 1 | 2018 | 42 | 0.610 |
Why?
|
| Hypothalamic Diseases | 4 | 2021 | 135 | 0.610 |
Why?
|
| Luteinizing Hormone | 21 | 2011 | 864 | 0.600 |
Why?
|
| Neurosecretory Systems | 5 | 2013 | 231 | 0.490 |
Why?
|
| Follicle Stimulating Hormone | 21 | 2011 | 738 | 0.440 |
Why?
|
| Receptors, LHRH | 9 | 2011 | 159 | 0.390 |
Why?
|
| Hypogonadism | 10 | 2021 | 798 | 0.390 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 248 | 0.390 |
Why?
|
| Hot Flashes | 3 | 2008 | 316 | 0.370 |
Why?
|
| Estradiol | 13 | 2006 | 2021 | 0.350 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 5 | 2008 | 98 | 0.330 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2018 | 113 | 0.300 |
Why?
|
| Postmenopause | 5 | 2006 | 2461 | 0.260 |
Why?
|
| Inhibins | 6 | 2005 | 211 | 0.230 |
Why?
|
| Endocrinology | 3 | 2016 | 443 | 0.210 |
Why?
|
| Androgens | 4 | 2018 | 1271 | 0.210 |
Why?
|
| Menopause | 2 | 2008 | 1621 | 0.200 |
Why?
|
| Menstruation | 2 | 2011 | 299 | 0.200 |
Why?
|
| Polycystic Ovary Syndrome | 7 | 2002 | 369 | 0.200 |
Why?
|
| Ovulation Induction | 6 | 2001 | 274 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 7276 | 0.190 |
Why?
|
| Activity Cycles | 1 | 2000 | 51 | 0.180 |
Why?
|
| Leuprolide | 2 | 2001 | 303 | 0.180 |
Why?
|
| Premenopause | 2 | 2018 | 1033 | 0.170 |
Why?
|
| Androgen Antagonists | 2 | 2018 | 1350 | 0.170 |
Why?
|
| Luteal Phase | 6 | 1998 | 147 | 0.170 |
Why?
|
| Progesterone | 9 | 2005 | 773 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 2 | 2016 | 744 | 0.170 |
Why?
|
| Menstrual Cycle | 4 | 1998 | 551 | 0.160 |
Why?
|
| Gonadotropins | 2 | 2002 | 241 | 0.160 |
Why?
|
| Reproductive Medicine | 1 | 1999 | 108 | 0.150 |
Why?
|
| Chorionic Gonadotropin | 4 | 2008 | 474 | 0.140 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 2866 | 0.130 |
Why?
|
| Neurotransmitter Agents | 1 | 1999 | 647 | 0.130 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 711 | 0.130 |
Why?
|
| Drug Compounding | 1 | 2016 | 242 | 0.130 |
Why?
|
| Follicular Phase | 5 | 1997 | 153 | 0.120 |
Why?
|
| Embryo Transfer | 1 | 1997 | 511 | 0.120 |
Why?
|
| Fertilization in Vitro | 2 | 2001 | 1284 | 0.120 |
Why?
|
| Pituitary Gland | 3 | 2013 | 665 | 0.110 |
Why?
|
| Hormones | 1 | 2016 | 884 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 3611 | 0.100 |
Why?
|
| Fertility Agents, Female | 2 | 2001 | 99 | 0.100 |
Why?
|
| Heterozygote | 4 | 2011 | 2790 | 0.090 |
Why?
|
| Female | 48 | 2021 | 379592 | 0.090 |
Why?
|
| Estrogens | 2 | 2008 | 1562 | 0.090 |
Why?
|
| Information Literacy | 1 | 2009 | 10 | 0.090 |
Why?
|
| Ovarian Diseases | 1 | 1990 | 139 | 0.090 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2008 | 25 | 0.080 |
Why?
|
| Ovary | 5 | 2011 | 981 | 0.080 |
Why?
|
| Azoospermia | 1 | 2008 | 27 | 0.080 |
Why?
|
| Administration, Intravaginal | 1 | 2008 | 147 | 0.080 |
Why?
|
| Cognition | 1 | 2006 | 6722 | 0.080 |
Why?
|
| Reproduction | 1 | 2013 | 668 | 0.080 |
Why?
|
| Periodicity | 4 | 1998 | 363 | 0.080 |
Why?
|
| Spermatogenesis | 1 | 2008 | 262 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2008 | 188 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 303 | 0.070 |
Why?
|
| Mass Media | 1 | 2009 | 303 | 0.070 |
Why?
|
| Humans | 52 | 2021 | 742088 | 0.070 |
Why?
|
| Ovulation | 4 | 2001 | 189 | 0.070 |
Why?
|
| Theca Cells | 1 | 2005 | 15 | 0.070 |
Why?
|
| Oophoritis | 1 | 2005 | 5 | 0.070 |
Why?
|
| School Health Services | 1 | 2009 | 375 | 0.060 |
Why?
|
| Adult | 33 | 2021 | 213712 | 0.060 |
Why?
|
| Perimenopause | 1 | 2006 | 139 | 0.060 |
Why?
|
| Ovarian Follicle | 2 | 2005 | 247 | 0.060 |
Why?
|
| Gonadal Steroid Hormones | 3 | 1997 | 711 | 0.060 |
Why?
|
| Atrophy | 1 | 2008 | 1576 | 0.060 |
Why?
|
| Vagina | 1 | 2008 | 825 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2011 | 1221 | 0.060 |
Why?
|
| Violence | 1 | 2009 | 908 | 0.050 |
Why?
|
| Mutation | 6 | 2013 | 29717 | 0.050 |
Why?
|
| Adolescent | 19 | 2021 | 85649 | 0.050 |
Why?
|
| Hormone Antagonists | 2 | 1999 | 107 | 0.050 |
Why?
|
| Aging | 1 | 2000 | 8626 | 0.050 |
Why?
|
| Follicular Fluid | 1 | 2001 | 87 | 0.050 |
Why?
|
| Pregnancy | 9 | 2001 | 29087 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 15530 | 0.050 |
Why?
|
| Phenotype | 4 | 2011 | 16331 | 0.040 |
Why?
|
| Institutional Practice | 1 | 1999 | 17 | 0.040 |
Why?
|
| Metoclopramide | 1 | 1999 | 50 | 0.040 |
Why?
|
| Dipeptides | 2 | 1999 | 409 | 0.040 |
Why?
|
| Sleep Deprivation | 1 | 2006 | 830 | 0.040 |
Why?
|
| Estrone | 1 | 2000 | 239 | 0.040 |
Why?
|
| Clonidine | 1 | 1999 | 164 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 379 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 177 | 0.040 |
Why?
|
| Dopamine Antagonists | 1 | 1999 | 296 | 0.040 |
Why?
|
| Middle Aged | 11 | 2021 | 213127 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2001 | 386 | 0.040 |
Why?
|
| Hypothalamus | 2 | 1994 | 1063 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2021 | 3587 | 0.040 |
Why?
|
| Protein Precursors | 2 | 2011 | 1154 | 0.040 |
Why?
|
| Naloxone | 1 | 1999 | 367 | 0.040 |
Why?
|
| Health Promotion | 1 | 2009 | 2194 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2011 | 849 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 782 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2006 | 2146 | 0.030 |
Why?
|
| Syndrome | 1 | 2001 | 3248 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 220 | 0.030 |
Why?
|
| Hospitals, General | 1 | 1999 | 749 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2001 | 983 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 1999 | 562 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2001 | 13921 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6483 | 0.030 |
Why?
|
| Pulsatile Flow | 3 | 2001 | 332 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 12958 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 6974 | 0.030 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 1993 | 53 | 0.030 |
Why?
|
| Infertility, Female | 1 | 1999 | 784 | 0.030 |
Why?
|
| Genotype | 3 | 2013 | 12946 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2005 | 2130 | 0.030 |
Why?
|
| Pregnancy, Multiple | 1 | 1993 | 217 | 0.030 |
Why?
|
| Insulin | 3 | 2002 | 6575 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 4187 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2006 | 12017 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 7901 | 0.030 |
Why?
|
| Receptors, FSH | 1 | 1991 | 28 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 1351 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2556 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 2699 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2013 | 62966 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2001 | 2924 | 0.020 |
Why?
|
| Body Mass Index | 4 | 2002 | 12695 | 0.020 |
Why?
|
| Semen | 1 | 1993 | 316 | 0.020 |
Why?
|
| Research | 1 | 1999 | 1999 | 0.020 |
Why?
|
| Reference Values | 4 | 2002 | 4982 | 0.020 |
Why?
|
| Weight Loss | 1 | 2001 | 2604 | 0.020 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 1 | 1989 | 41 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2011 | 250 | 0.020 |
Why?
|
| Fertility | 1 | 1994 | 770 | 0.020 |
Why?
|
| Infertility, Male | 1 | 1993 | 407 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2011 | 272 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1989 | 163 | 0.020 |
Why?
|
| Amino Acid Sequence | 4 | 2004 | 13814 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1993 | 876 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1992 | 703 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 4465 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 10943 | 0.020 |
Why?
|
| Sperm Motility | 1 | 2008 | 253 | 0.020 |
Why?
|
| DNA | 3 | 2011 | 7289 | 0.020 |
Why?
|
| Testosterone | 3 | 2008 | 2401 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 2384 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2021 | 21719 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 3862 | 0.020 |
Why?
|
| Feedback | 1 | 1990 | 793 | 0.020 |
Why?
|
| Aged | 5 | 2021 | 162944 | 0.020 |
Why?
|
| Women's Health | 1 | 2016 | 2034 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2001 | 4229 | 0.020 |
Why?
|
| Base Sequence | 3 | 2004 | 12797 | 0.020 |
Why?
|
| Massachusetts | 1 | 1999 | 8662 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 1310 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 9941 | 0.020 |
Why?
|
| Pedigree | 2 | 2006 | 4646 | 0.020 |
Why?
|
| Testis | 1 | 2008 | 800 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 17400 | 0.020 |
Why?
|
| Luteinizing Hormone, beta Subunit | 1 | 2004 | 11 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, beta Subunit | 1 | 2004 | 58 | 0.020 |
Why?
|
| Young Adult | 3 | 2021 | 56350 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2006 | 340 | 0.020 |
Why?
|
| Spermatozoa | 1 | 2008 | 625 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 2004 | 180 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2018 | 3861 | 0.020 |
Why?
|
| Survivors | 1 | 1994 | 2286 | 0.010 |
Why?
|
| Prognosis | 2 | 2001 | 29010 | 0.010 |
Why?
|
| Cholesterol | 1 | 1993 | 2895 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2013 | 77098 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2004 | 162 | 0.010 |
Why?
|
| Organ Size | 1 | 2008 | 2253 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2011 | 6540 | 0.010 |
Why?
|
| Sleep | 1 | 1999 | 4604 | 0.010 |
Why?
|
| Diazoxide | 1 | 2002 | 57 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2004 | 235 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2001 | 15108 | 0.010 |
Why?
|
| Breast | 1 | 2011 | 1958 | 0.010 |
Why?
|
| Male | 12 | 2013 | 349538 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 2001 | 4929 | 0.010 |
Why?
|
| Androstenedione | 1 | 2001 | 131 | 0.010 |
Why?
|
| Macromolecular Substances | 2 | 1994 | 1456 | 0.010 |
Why?
|
| Recurrence | 1 | 2013 | 8333 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2004 | 1097 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4801 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 1792 | 0.010 |
Why?
|
| Smell | 1 | 2001 | 243 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 1160 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1998 | 82 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 35342 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2001 | 642 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2010 | 3740 | 0.010 |
Why?
|
| Half-Life | 1 | 1999 | 658 | 0.010 |
Why?
|
| Gene Expression | 1 | 2011 | 7790 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2011 | 5978 | 0.010 |
Why?
|
| Neuroprotective Agents | 1 | 2004 | 941 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 8829 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2001 | 53187 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1777 | 0.010 |
Why?
|
| Risk Factors | 2 | 1993 | 72145 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 2186 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 1676 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 8297 | 0.010 |
Why?
|
| Freezing | 1 | 1996 | 303 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 1887 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 7770 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 18112 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 3744 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 20774 | 0.010 |
Why?
|
| Calibration | 1 | 1996 | 815 | 0.010 |
Why?
|
| Animals | 5 | 2011 | 168561 | 0.010 |
Why?
|
| Follistatin | 1 | 1994 | 141 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 1407 | 0.010 |
Why?
|
| Biological Assay | 1 | 1996 | 652 | 0.010 |
Why?
|
| Child | 1 | 2021 | 77478 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 2471 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 918 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2030 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 6474 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1993 | 2255 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4328 | 0.010 |
Why?
|
| Glycopeptides | 1 | 1991 | 224 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1996 | 14720 | 0.010 |
Why?
|
| Body Fluids | 1 | 1991 | 319 | 0.010 |
Why?
|
| Culture Media | 1 | 1991 | 902 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 23320 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 19223 | 0.000 |
Why?
|
| Equipment Contamination | 1 | 1989 | 183 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2011 | 40450 | 0.000 |
Why?
|
| Forearm | 1 | 1989 | 407 | 0.000 |
Why?
|
| Catheters, Indwelling | 1 | 1989 | 425 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1994 | 2260 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1993 | 5180 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1989 | 2271 | 0.000 |
Why?
|
| Mice | 1 | 2011 | 81045 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1992 | 6452 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 6608 | 0.000 |
Why?
|
| Stroke | 1 | 2004 | 9963 | 0.000 |
Why?
|
| Swine | 1 | 1991 | 5934 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2004 | 23387 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1389 | 0.000 |
Why?
|
| United States | 1 | 2008 | 69693 | 0.000 |
Why?
|
| Bacteria | 1 | 1989 | 2102 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1991 | 5019 | 0.000 |
Why?
|
| Cell Line | 1 | 1991 | 15994 | 0.000 |
Why?
|
Concepts
(247)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_